Treats hypertension. ANDA 202297, held by Yung Shin Pharm. Clonidine Hydrochloride.
As of Nov 16, 2026, ANDA 202297 (Clonidine Hydrochloride), held by Yung Shin Pharm, was first approved by FDA on Jun 13, 2013, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE Clonidine hydrochloride tablets, USP are indicated in the treatment of hypertension. Clonidine hydrochloride tablets, USP may be employed alone or concomitantly with other antihypertensive agents.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 13, 2013 | Original application | Approved | None posted |
| Clonidine Hydrochloride0.1MG · tablet;oral | Clonidine Hydrochloride | Rx |
| Clonidine Hydrochloride0.2MG · tablet;oral | Clonidine Hydrochloride | Rx |
| Clonidine Hydrochloride0.3MG · tablet;oral | Clonidine Hydrochloride | Rx |
| Dec 23, 2024 | Supplement 6Manufacturing | Approved | None posted |
| Jun 13, 2013 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters